Logo image of SALME.OL

SALMON EVOLUTION ASA (SALME.OL) Stock Fundamental Analysis

OSL:SALME - Euronext Oslo - NO0010892094 - Common Stock - Currency: NOK

6.09  +0.02 (+0.33%)

Fundamental Rating

3

SALME gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 55 industry peers in the Food Products industry. SALME may be in some trouble as it scores bad on both profitability and health. SALME is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SALME has reported negative net income.
In the past year SALME had a positive cash flow from operations.
In the past 5 years SALME always reported negative net income.
SALME had negative operating cash flow in 4 of the past 5 years.
SALME.OL Yearly Net Income VS EBIT VS OCF VS FCFSALME.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M

1.2 Ratios

SALME has a Return On Assets of -2.87%. This is in the lower half of the industry: SALME underperforms 72.73% of its industry peers.
With a Return On Equity value of -4.54%, SALME is not doing good in the industry: 72.73% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -2.87%
ROE -4.54%
ROIC N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
SALME.OL Yearly ROA, ROE, ROICSALME.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

The Gross Margin of SALME (65.28%) is better than 94.55% of its industry peers.
SALME's Gross Margin has declined in the last couple of years.
SALME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
SALME.OL Yearly Profit, Operating, Gross MarginsSALME.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

SALME does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SALME has been increased compared to 1 year ago.
The number of shares outstanding for SALME has been increased compared to 5 years ago.
SALME has a better debt/assets ratio than last year.
SALME.OL Yearly Shares OutstandingSALME.OL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
SALME.OL Yearly Total Debt VS Total AssetsSALME.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

Based on the Altman-Z score of 1.42, we must say that SALME is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.42, SALME is doing worse than 69.09% of the companies in the same industry.
A Debt/Equity ratio of 0.39 indicates that SALME is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.39, SALME is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z 1.42
ROIC/WACCN/A
WACC7.97%
SALME.OL Yearly LT Debt VS Equity VS FCFSALME.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

SALME has a Current Ratio of 1.80. This is a normal value and indicates that SALME is financially healthy and should not expect problems in meeting its short term obligations.
SALME has a Current ratio of 1.80. This is in the better half of the industry: SALME outperforms 72.73% of its industry peers.
A Quick Ratio of 1.29 indicates that SALME should not have too much problems paying its short term obligations.
SALME has a Quick ratio of 1.29. This is in the better half of the industry: SALME outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.8
Quick Ratio 1.29
SALME.OL Yearly Current Assets VS Current LiabilitesSALME.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.43% over the past year.
SALME shows a strong growth in Revenue. In the last year, the Revenue has grown by 67.45%.
The Revenue has been growing by 238.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3806.9%
Revenue 1Y (TTM)67.45%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%-50.46%

3.2 Future

The Earnings Per Share is expected to grow by 80.92% on average over the next years. This is a very strong growth
SALME is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.16% yearly.
EPS Next Y109.36%
EPS Next 2Y74.45%
EPS Next 3Y92.99%
EPS Next 5Y80.92%
Revenue Next Year15.78%
Revenue Next 2Y30.97%
Revenue Next 3Y51.3%
Revenue Next 5Y48.16%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SALME.OL Yearly Revenue VS EstimatesSALME.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
SALME.OL Yearly EPS VS EstimatesSALME.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SALME. In the last year negative earnings were reported.
SALME is valuated quite expensively with a Price/Forward Earnings ratio of 53.06.
SALME's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. SALME is more expensive than 76.36% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of SALME to the average of the S&P500 Index (37.36), we can say SALME is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 53.06
SALME.OL Price Earnings VS Forward Price EarningsSALME.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SALME is valued more expensive than 83.64% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 79.09
SALME.OL Per share dataSALME.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

SALME's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SALME's earnings are expected to grow with 92.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.45%
EPS Next 3Y92.99%

More info and screens

0

5. Dividend

5.1 Amount

SALME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SALMON EVOLUTION ASA

OSL:SALME (7/23/2025, 4:16:37 PM)

6.09

+0.02 (+0.33%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-19 2025-08-19
Inst Owners21.67%
Inst Owner ChangeN/A
Ins Owners2.19%
Ins Owner ChangeN/A
Market Cap2.82B
Analysts85
Price Target9.21 (51.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-742.73%
Min EPS beat(2)-1265.05%
Max EPS beat(2)-220.42%
EPS beat(4)1
Avg EPS beat(4)-391.97%
Min EPS beat(4)-1265.05%
Max EPS beat(4)6.04%
EPS beat(8)2
Avg EPS beat(8)-212.49%
EPS beat(12)6
Avg EPS beat(12)-132.81%
EPS beat(16)9
Avg EPS beat(16)-97.7%
Revenue beat(2)1
Avg Revenue beat(2)-20.97%
Min Revenue beat(2)-43.93%
Max Revenue beat(2)1.98%
Revenue beat(4)1
Avg Revenue beat(4)-21.8%
Min Revenue beat(4)-43.93%
Max Revenue beat(4)1.98%
Revenue beat(8)3
Avg Revenue beat(8)-21.1%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.22%
PT rev (3m)-7.74%
EPS NQ rev (1m)-4.77%
EPS NQ rev (3m)-168.76%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-4.77%
Revenue NQ rev (3m)-35.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 53.06
P/S 6.71
P/FCF N/A
P/OCF 73.03
P/B 1.3
P/tB 1.35
EV/EBITDA 79.09
EPS(TTM)-0.22
EYN/A
EPS(NY)0.11
Fwd EY1.88%
FCF(TTM)-1.14
FCFYN/A
OCF(TTM)0.08
OCFY1.37%
SpS0.91
BVpS4.69
TBVpS4.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.87%
ROE -4.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.28%
FCFM N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA 19.69
Cap/Depr 717.36%
Cap/Sales 135.14%
Interest Coverage N/A
Cash Conversion 89.28%
Profit Quality N/A
Current Ratio 1.8
Quick Ratio 1.29
Altman-Z 1.42
F-Score4
WACC7.97%
ROIC/WACCN/A
Cap/Depr(3y)4495.02%
Cap/Depr(5y)15899.7%
Cap/Sales(3y)642.51%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3806.9%
EPS Next Y109.36%
EPS Next 2Y74.45%
EPS Next 3Y92.99%
EPS Next 5Y80.92%
Revenue 1Y (TTM)67.45%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%-50.46%
Revenue Next Year15.78%
Revenue Next 2Y30.97%
Revenue Next 3Y51.3%
Revenue Next 5Y48.16%
EBIT growth 1Y64.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73454.1%
EBIT Next 3Y1493.28%
EBIT Next 5Y543.81%
FCF growth 1Y26.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.89%
OCF growth 3YN/A
OCF growth 5YN/A